ABPRO Holdings IncNASDAQ:ABPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE3.1800
- TODAY'S CHANGE (%)-0.2300 (-6.7449%)
- Bid / Lots3.2500/ 2
- Ask / Lots3.6900/ 1
- Open / Previous Close3.3400 / 3.4100
- Day Range
- 52 Week Range
- Volume35,734
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABP |
|---|---|---|
| 09:55 ET | 1375 | 3.34 |
| 09:57 ET | 2700 | 3.5102 |
| 10:00 ET | 787 | 3.4155 |
| 10:09 ET | 100 | 3.23 |
| 11:09 ET | 100 | 3.45 |
| 11:21 ET | 326 | 3.24 |
| 11:54 ET | 579 | 3.23 |
| 12:37 ET | 1110 | 3.3383 |
| 12:46 ET | 799 | 3.23 |
| 12:48 ET | 535 | 3.2 |
| 12:51 ET | 500 | 3.25 |
| 12:57 ET | 4401 | 3.31 |
| 01:00 ET | 1004 | 3.19 |
| 01:45 ET | 200 | 3.34 |
| 02:02 ET | 448 | 3.3 |
| 02:05 ET | 3200 | 3.35 |
| 02:07 ET | 200 | 3.372 |
| 02:14 ET | 2795 | 3.59 |
| 02:16 ET | 2800 | 3.3601 |
| 02:18 ET | 1568 | 3.4 |
| 02:20 ET | 800 | 3.35 |
| 02:50 ET | 100 | 3.3 |
| 02:52 ET | 116 | 3.45 |
| 03:19 ET | 400 | 3.3501 |
| 03:21 ET | 814 | 3.3 |
| 03:48 ET | 301 | 3.35 |
| 03:53 ET | 100 | 3.31 |
| 04:00 ET | 1902 | 3.18 |
Nov 13, 2024
*DJ News On Atlantic Coastal Acquisition Corp. II (ACAB) Now Under ABP, from 5:08PM ET on Wednesday Nov 13, 2024 by Dow Jones
5:08PM ET on Wednesday Nov 13, 2024 by Dow Jones*DJ News On Abpro Corp. (ABPC.XX) Now Under ABP, from 5:08PM ET on Wednesday Nov 13, 2024 by Dow Jones
5:08PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ABPRO Holdings Inc | 25.6M | 22.8x | --- |
GeoVax Labs Inc | 25.5M | -0.3x | --- |
Athira Pharma Inc | 25.3M | -0.2x | --- |
Ocean Biomedical Inc | 24.7M | -0.2x | --- |
Mink Therapeutics Inc | 27.3M | -1.8x | --- |
Lisata Therapeutics Inc | 23.7M | -1.1x | --- |
Company Information
Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The Company is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.
Contact Information
- Headquarters
- 6 St Johns Lane, Floor 5NEW YORK, NY, United States 10013
- Phone
- 248-890-7200
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Shahraab Ahmad
- President, Director
- Burt Jordan
- Chief Financial Officer, Director
- Jason Chryssicas
- Chief Strategy Officer, Director
- Anthony Eisenberg
- Director
- Curtis Collar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 8.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.14 |
Book Value | $7.94 |
P/E Ratio | 22.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
